AstraZeneca announced that it has entered into a definitive agreement with Genzyme to divest Caprelsa (vandetanib), a rare disease medicine....
The antitumor activity of vandetanib [a multiple signal transduction inhibitor including the RET tyrosine kinase, epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) receptor (VEGFR),...
Introduction: Traditional therapies for advanced or metastatic progressive medullary thyroid cancer (pMTC) are poor effective.
Purpose: We conducted a post hoc analysis of the vandetanib phase III trial involving patients with advanced medullary thyroid cancer (MTC) to assess the efficacy and safety of vandetanib in patients with progressive and symptomatic MTC.
Purpose: Vandetanib is well-tolerated in patients with advanced medullary thyroid carcinoma (MTC). Long-term outcomes and mechanisms of MTC progression have not been reported previously
Caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Caprelsa is indicated in adults, children and adolescents aged 5 years and older. For patients in whom Rearranged during Transfection (RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision (see important information in sections 4.4 and 5.1).
The National Institute for Health and Care Excellence (NICE) announced in draft guidance that it was not recommending Sanof's Caprelsa...
A new study shows that the chemotherapy drug vandetanib Caprelsa (vandetanib) from AstraZeneca, may extend life for some Thyroid Cancer...
In updated guidance based on its latest review, NICE has announced that Caprelsa (vandetanib), from Genzyme/Sanofi, is not recommended, within...